tetano
Editor, Senior Moderator
J Popul Ther Clin Pharmacol
. 2020 Jun 3;27(S Pt 1):e5-e10.
doi: 10.15586/jptcp.v27iSP1.684.
The Comparison of the Effectiveness of lincocin? and azitro? in the Treatment of covid-19-associated Pneumonia: A Prospective Study
Oguz Guvenmez[SUP] 1 [/SUP], H?seyin Keskin[SUP] 2 [/SUP], Burak Ay[SUP] 3 [/SUP], Suayip Birinci[SUP] 4 [/SUP], Muhammed Furkan Kanca[SUP] 5 [/SUP]
Affiliations
Abstract
The COVID-19 virus has spread rapidly around the world and there are many patients in multiple countries. Great efforts have been made to find effective medications against the COVID-19. This study aims to compare the effectiveness of LINCOCIN? and AZITRO? in the treatment of COVID-19 associated pneumonia. A total of 24 hospitalized patients aged between 30-80 years who were admitted to the Tarsus Medical Park Hospital between February to March 2020 was included in the study. The patients were divided into LINCOCIN? and AZITRO? treatment groups. Bronchoalveolar-lavage PCR results were compared after treatment. The mean age was 58.4?15.4 years in the LINCOCIN? group and 59.1?16.6 years in the AZITRO? group. In the LINCOCIN? group, the rate of males was 66.7% and it was 58.3% in the AZITRO? group. There were no statistical differences in terms of age and gender between the groups. On the 6th day after starting treatment, negative bronchoalveolar PCR result was 83.3% in the LINCOCIN? group and 33.3% in the AZITRO? group. The negative bronchoalveolar PCR proportion was significantly higher in the LINCOCIN? group than in the AZITRO? group. LINCOCIN? usage may be more appropriate in the treatment of COVID-19 associated pneumonia. Further studies with a large sample size should clarify these results.
Keywords: COVID-19; coronavirus; medication; pneumonia; treatment.
. 2020 Jun 3;27(S Pt 1):e5-e10.
doi: 10.15586/jptcp.v27iSP1.684.
The Comparison of the Effectiveness of lincocin? and azitro? in the Treatment of covid-19-associated Pneumonia: A Prospective Study
Oguz Guvenmez[SUP] 1 [/SUP], H?seyin Keskin[SUP] 2 [/SUP], Burak Ay[SUP] 3 [/SUP], Suayip Birinci[SUP] 4 [/SUP], Muhammed Furkan Kanca[SUP] 5 [/SUP]
Affiliations
- PMID: 32543164
- DOI: 10.15586/jptcp.v27iSP1.684
Abstract
The COVID-19 virus has spread rapidly around the world and there are many patients in multiple countries. Great efforts have been made to find effective medications against the COVID-19. This study aims to compare the effectiveness of LINCOCIN? and AZITRO? in the treatment of COVID-19 associated pneumonia. A total of 24 hospitalized patients aged between 30-80 years who were admitted to the Tarsus Medical Park Hospital between February to March 2020 was included in the study. The patients were divided into LINCOCIN? and AZITRO? treatment groups. Bronchoalveolar-lavage PCR results were compared after treatment. The mean age was 58.4?15.4 years in the LINCOCIN? group and 59.1?16.6 years in the AZITRO? group. In the LINCOCIN? group, the rate of males was 66.7% and it was 58.3% in the AZITRO? group. There were no statistical differences in terms of age and gender between the groups. On the 6th day after starting treatment, negative bronchoalveolar PCR result was 83.3% in the LINCOCIN? group and 33.3% in the AZITRO? group. The negative bronchoalveolar PCR proportion was significantly higher in the LINCOCIN? group than in the AZITRO? group. LINCOCIN? usage may be more appropriate in the treatment of COVID-19 associated pneumonia. Further studies with a large sample size should clarify these results.
Keywords: COVID-19; coronavirus; medication; pneumonia; treatment.